NMIBC Treatment
Aug 30, 2024
NMIBC Treatment Paradigm Evolution: A Look At The Clinical Development Shift From High-Risk Bcg Unresponsive To Untapped High-Risk Bcg Naïve And Intermediate-Risk NMIBC
A high cure rate characterizes Non-muscle Invasive Bladder Cancer (NMIBC), yet there is a notable risk of recurrence and progression to muscle-invasive disease. Effective NMIBC management involves precise local resection, staging, and a risk-based approach with intravesical agents. The conventional gold standard fo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
